Aslan Historical Financial Ratios

ASLN Stock  USD 0.47  0.01  2.17%   
Aslan Pharmaceuticals is presently reporting on over 122 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, Days Sales Outstanding of 5.7 or Average Payables of 7.5 M will help investors to properly organize and evaluate Aslan Pharmaceuticals financial condition quickly.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aslan Pharmaceuticals Ltd. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

About Aslan Financial Ratios Analysis

Aslan PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Aslan Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Aslan financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Aslan Pharmaceuticals history.

Aslan Pharmaceuticals Financial Ratios Chart

Aslan Pharmaceuticals Ltd financial ratios usually calculated using numerical values taken directly from Aslan Pharmaceuticals financial statements such as income statements or balance sheets. They help investors to obtain meaningful information about Aslan Pharmaceuticals. Most financial ratios help to conduct quantitative analysis to assess vital information about the company's valuation as well as profitability and liquidity indicators such as leverage, growth, profit margins, and different types of rates of return.
At this time, Aslan Pharmaceuticals' Average Payables is very stable compared to the past year. As of the 24th of April 2024, Stock Based Compensation To Revenue is likely to grow to 0.21, while Price To Sales Ratio is likely to drop 0.78.
Add Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Aslan Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Aslan Pharmaceuticals sales, a figure that is much harder to manipulate than other Aslan Pharmaceuticals Ltd multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company’s stock price to its revenues, calculated by dividing the company’s market cap by its total sales or revenue over a 12-month period.

Average Payables

The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.
Most ratios from Aslan Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Aslan Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aslan Pharmaceuticals Ltd. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
At this time, Aslan Pharmaceuticals' Average Payables is very stable compared to the past year. As of the 24th of April 2024, Stock Based Compensation To Revenue is likely to grow to 0.21, while Price To Sales Ratio is likely to drop 0.78.
 2023 2024 (projected)
Graham Number6.996.64
Receivables Turnover63.031.56

Aslan Pharmaceuticals fundamentals Correlations

-0.270.25-0.170.53-0.31-0.3-0.58-0.41-0.270.97-0.340.32-0.320.64-0.260.35-0.15-0.780.41-0.14-0.5-0.2-0.290.34-0.2
-0.270.22-0.12-0.110.92-0.150.15-0.171.0-0.33-0.160.42-0.09-0.43-0.220.24-0.110.080.18-0.10.36-0.140.5-0.97-0.14
0.250.22-0.780.320.19-0.73-0.790.220.220.02-0.710.8-0.73-0.51-1.00.87-0.260.3-0.2-0.260.29-0.84-0.11-0.21-0.84
-0.17-0.12-0.78-0.15-0.110.980.64-0.21-0.120.00.97-0.660.980.420.78-0.93-0.31-0.190.23-0.31-0.240.87-0.10.140.87
0.53-0.110.32-0.150.05-0.19-0.59-0.13-0.110.47-0.20.64-0.210.38-0.340.38-0.34-0.340.14-0.35-0.28-0.21-0.110.02-0.21
-0.310.920.19-0.110.05-0.120.18-0.120.92-0.37-0.140.49-0.08-0.46-0.190.23-0.060.130.13-0.050.55-0.140.41-0.97-0.14
-0.3-0.15-0.730.98-0.19-0.120.64-0.1-0.15-0.141.0-0.671.00.280.73-0.94-0.33-0.010.13-0.33-0.150.83-0.130.150.83
-0.580.15-0.790.64-0.590.180.64-0.110.15-0.410.63-0.630.66-0.020.8-0.740.240.080.10.250.170.690.24-0.140.69
-0.41-0.170.22-0.21-0.13-0.12-0.1-0.11-0.17-0.48-0.010.0-0.12-0.5-0.220.180.020.59-1.0-0.030.35-0.21-0.180.13-0.22
-0.271.00.22-0.12-0.110.92-0.150.15-0.17-0.33-0.160.42-0.09-0.43-0.220.24-0.110.080.18-0.10.36-0.140.5-0.97-0.14
0.97-0.330.020.00.47-0.37-0.14-0.41-0.48-0.33-0.180.14-0.160.78-0.030.16-0.09-0.880.47-0.08-0.58-0.01-0.270.41-0.01
-0.34-0.16-0.710.97-0.2-0.141.00.63-0.01-0.16-0.18-0.670.990.240.71-0.92-0.340.040.04-0.34-0.110.82-0.150.160.82
0.320.420.8-0.660.640.49-0.67-0.630.00.420.14-0.67-0.66-0.28-0.810.85-0.150.010.0-0.160.2-0.730.15-0.46-0.73
-0.32-0.09-0.730.98-0.21-0.081.00.66-0.12-0.09-0.160.99-0.660.260.73-0.94-0.32-0.010.15-0.32-0.140.83-0.080.10.83
0.64-0.43-0.510.420.38-0.460.28-0.02-0.5-0.430.780.24-0.280.260.5-0.330.01-0.870.490.02-0.810.44-0.070.460.44
-0.26-0.22-1.00.78-0.34-0.190.730.8-0.22-0.22-0.030.71-0.810.730.5-0.880.26-0.290.20.26-0.280.840.120.20.84
0.350.240.87-0.930.380.23-0.94-0.740.180.240.16-0.920.85-0.94-0.33-0.880.080.04-0.190.070.18-0.870.08-0.23-0.87
-0.15-0.11-0.26-0.31-0.34-0.06-0.330.240.02-0.11-0.09-0.34-0.15-0.320.010.260.08-0.06-0.091.00.05-0.270.40.05-0.27
-0.780.080.3-0.19-0.340.13-0.010.080.590.08-0.880.040.01-0.01-0.87-0.290.04-0.06-0.58-0.080.62-0.24-0.02-0.14-0.24
0.410.18-0.20.230.140.130.130.1-1.00.180.470.040.00.150.490.2-0.19-0.09-0.58-0.05-0.340.240.15-0.130.24
-0.14-0.1-0.26-0.31-0.35-0.05-0.330.25-0.03-0.1-0.08-0.34-0.16-0.320.020.260.071.0-0.08-0.050.04-0.260.410.04-0.26
-0.50.360.29-0.24-0.280.55-0.150.170.350.36-0.58-0.110.2-0.14-0.81-0.280.180.050.62-0.340.04-0.25-0.02-0.44-0.25
-0.2-0.14-0.840.87-0.21-0.140.830.69-0.21-0.14-0.010.82-0.730.830.440.84-0.87-0.27-0.240.24-0.26-0.25-0.120.161.0
-0.290.5-0.11-0.1-0.110.41-0.130.24-0.180.5-0.27-0.150.15-0.08-0.070.120.080.4-0.020.150.41-0.02-0.12-0.47-0.12
0.34-0.97-0.210.140.02-0.970.15-0.140.13-0.970.410.16-0.460.10.460.2-0.230.05-0.14-0.130.04-0.440.16-0.470.16
-0.2-0.14-0.840.87-0.21-0.140.830.69-0.22-0.14-0.010.82-0.730.830.440.84-0.87-0.27-0.240.24-0.26-0.251.0-0.120.16
Click cells to compare fundamentals

Aslan Pharmaceuticals Account Relationship Matchups

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Aslan Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Aslan Pharmaceuticals' short interest history, or implied volatility extrapolated from Aslan Pharmaceuticals options trading.

Pair Trading with Aslan Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aslan Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aslan Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Aslan Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aslan Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aslan Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aslan Pharmaceuticals Ltd to buy it.
The correlation of Aslan Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aslan Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aslan Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aslan Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Aslan Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aslan Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aslan Pharmaceuticals Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aslan Pharmaceuticals Ltd Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aslan Pharmaceuticals Ltd. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.

Complementary Tools for Aslan Stock analysis

When running Aslan Pharmaceuticals' price analysis, check to measure Aslan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aslan Pharmaceuticals is operating at the current time. Most of Aslan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aslan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aslan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aslan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Stocks Directory
Find actively traded stocks across global markets
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Is Aslan Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aslan Pharmaceuticals. If investors know Aslan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aslan Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.75)
Revenue Per Share
0.729
Return On Assets
(0.64)
Return On Equity
(4.27)
The market value of Aslan Pharmaceuticals is measured differently than its book value, which is the value of Aslan that is recorded on the company's balance sheet. Investors also form their own opinion of Aslan Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aslan Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aslan Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aslan Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aslan Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aslan Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aslan Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.